Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Its clinical program in the 1990s in Croatia (intended for approval for Crohns disease, an autoimmune inflammatory bowel disease) stopped at Phase 2
Retatrutide is an investigational medication being studied for obesity and metabolic health
Phase III trials typically last one to four years with carefully selected participants who often exclude the complex cases that physicians encounter in practice
Because the peptide works specifically on fat tissue without affecting other systems, protocols can be designed purely around fat metabolism optimization without concerns about managing glucose, IGF-1, or growth-related effects
US$ 22.51
US$ 26.61
US$ 25.33
